Peripheral Immune Tolerance and Regulatory T Cells: Lessons from the 2025 Nobel Prize in Physiology or Medicine

MOLECULAR BASIS OF TREGS FUNCTION

Treg acts as a dynamic moderator of immune responses through a combination of cell-contact-dependent and cytokine-mediated mechanisms. Key pathways include:^6,7

• Cytokine-mediated suppression: Secretion of IL-10, transforming growth factor-β and IL-35 inhibits effector T-cell proliferation and dampens dendritic cell activation

• IL-2 consumption: Tregs express high-affinity IL-2 receptors, sequestering IL-2 and thereby limiting effector T-cell expansion

• Metabolic reprogramming: Through CD39/CD73-mediated adenosine generation, Tregs modulate the inflammatory conditions

• CTLA-4 engagement: By downregulating CD80/CD86 on antigen-presenting cells, Tregs attenuate costimulatory signalling, a key brake on T-cell activation

• Epigenetic stability: FOXP3 coordinates a transcriptional network that sustains the suppressive phenotype, reinforced by epigenetic modifications at the TSDR (Treg-specific demethylated region) locus.

Together, the above mechanisms create a multilayered regulatory circuit that maintains immune equilibrium without compromising pathogen defense.^6,7

CLINICAL AND TRANSLATIONAL IMPLICATIONS

The delineation of the Treg–FOXP3 axis has reshaped clinical immunology and opened novel therapeutic frontiers:

• Autoimmunity: Augmenting Treg numbers or function represents a promising approach in diseases such as type 1 diabetes, systemic lupus erythematosus and multiple sclerosis⁸

• Transplantation: Ex vivo–expanded autologous Tregs are being trialed to promote graft tolerance while minimising pharmacologic immunosuppression⁹

• Cancer: In contrast, tumour-infiltrating Tregs can suppress anti-tumour immunity; selective Treg depletion or blockade of FOXP3/CTLA-4 pathways may enhance immunotherapeutic efficacy¹⁰

• Chronic inflammation: Understanding Treg plasticity in inflamed tissues provides insight into immune resolution and tissue repair mechanisms¹¹

• Next-generation immune engineering: Emerging approaches include CAR-Tregs, CRISPR-based FOXP3 stabilisation and epigenetic reprogramming to generate disease-specific regulatory cell products.^12,13

These applications illustrate how a fundamental discovery in immunoregulation can transcend basic biology to influence therapeutic innovation.

The recognition of Tregs transformed immunology from a discipline focused on immune activation to one centred on immune balance. It reframed tolerance as an active biological process governed by identifiable cells, genes and signalling pathways. Equally important, this work exemplifies how rare disease models and fundamental research can yield broadly applicable insights. The Treg paradigm now underpins therapeutic strategies across multiple medical specialties, from endocrinology to oncology.

CONCLUSION

The 2025 Nobel Prize in Physiology or Medicine highlights one of the most consequential advances in modern immunology, the discovery that immune tolerance is actively maintained by Tregs under the control of FOXP3. This work bridged basic science and clinical medicine, reshaping the understanding of autoimmunity, transplantation and cancer. As translational immunology advances towards programmable immune modulation, the principles established by these discoveries will remain foundational. They underscore a central lesson of immune biology, that health depends not only on the ability to respond, but also equally on the capacity for restraint.